drugset
Drugs / SHR4640
last change Feb 2026 re-read 9 days ago

SHR4640

also known as Ruzinurad

Small molecule targets SLC22A12 via inhibition

Developed for
gout
Investigated by
Jiangsu HengRui Medicine Co., Ltd. · Atridia Pty Ltd.

Trials 19

today NCT07362355 · Ph 2 NCT06196580 · Ph 1 NCT05954169 · Ph 1 NCT05513976 · Ph 2 NCT04850638 · Ph 1 NCT04956432 · Ph 3 NCT04620408 · Ph 1 NCT04586803 · Ph 1 NCT04305392 · Ph 1 NCT04260373 · Ph 1 NCT04180982 · Ph 2 NCT04157959 · Ph 1 NCT04052932 · Ph 3 NCT03185793 · Ph 2 NCT03211403 · Ph 1 NCT03131583 · Ph 1 NCT03015948 · Ph 1 NCT02890966 · Ph 1 NCT02815839 · Ph 1
201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 113 trials
Phase 1 NCT06196580 Jan → Feb 2024 gout Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT05954169 Aug 2023 → Jul 2024 — Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT04850638 Jun → Sep 2021 — Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT04620408 Dec 2020 → Jan 2021 — Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT04586803 Oct → Nov 2020 gout Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT04305392 Aug 2020 → Dec 2022 — Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT04260373 Mar → Apr 2020 — Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 1 NCT04157959 Oct 2019 → Jun 2020 — Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 1 NCT03211403 Jul 2017 → Feb 2018 gout Atridia Pty Ltd. Completed No outcome recorded
Phase 1 NCT03131583 Feb 2017 → Jan 2018 gout Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 24 trials · 1 met primary
Phase 2 NCT07362355 Feb 2026 → Jul 2027 expected gout Jiangsu HengRui Medicine Co., Ltd. Recruiting No outcome recorded
Phase 2 NCT05513976 Sep 2022 → May 2023 gout Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 2 NCT04180982 Dec 2019 → Jul 2020 — Jiangsu HengRui Medicine Co., Ltd. Unknown No outcome recorded
Phase 2 NCT03185793 Jul 2017 → Jul 2018 — Jiangsu HengRui Medicine Co., Ltd. Completed Met primary
Phase 32 trials
Phase 3 NCT04956432 Jun 2021 → Dec 2023 gout Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded
Phase 3 NCT04052932 Jul 2019 → Jul 2021 gout Jiangsu HengRui Medicine Co., Ltd. Completed No outcome recorded

Evidence & citations 6 cited values

Every value below carries the sentence it was read from. 21 sources stand behind the page.

FieldValueCited text
Known as SHR4640 ClinicalTrials.gov intervention name — accepted as the source's own label NCT07362355 ↗
18

NCT03211403 ↗

NCT04157959 ↗

NCT04586803 ↗

NCT06196580 ↗

NCT02815839 ↗

NCT04052932 ↗

NCT05954169 ↗

NCT04850638 ↗

NCT05513976 ↗

NCT04180982 ↗

Show 8 more sources
Known as Ruzinurad ChEMBL registry synonym — accepted as the source's own label CHEMBL3746329 ↗
Action Inhibit “a highly selective urate transporter 1 inhibitor” PMID 33693494 ↗ Nov 2021
1

“Solute carrier family 22 member 12 inhibitor” CHEMBL3746329 ↗
Modality Small molecule — CHEMBL3746329 ↗
Route Oral “oral administration” NCT02890966 ↗
Target SLC22A12 “Solute carrier family 22 member 12 inhibitor” CHEMBL3746329 ↗